Neoadjuvant Immune Checkpoint Inhibitor plus Chemotherapy for Resectable Non-small Cell Lung Cancer in Real World

被引：0
|
作者：
Chen, C. [1 ]
机构：
[1] Zunyi Med Univ, Affiliated Hosp, Zunyi, Guizhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-small cell lung cancer; Neoadjuvant therapy; PD-1; inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-24
引用
收藏
页码：S579 / S580
页数：2
相关论文
共 50 条
  • [31] The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
    Long Jiang
    Jia Huang
    Shanshan Jiang
    Wenwen Rong
    Yaofeng Shen
    Chongwu Li
    Yu Tian
    Junwei Ning
    Xiaoke Chen
    Yunhai Yang
    Zhengping Ding
    Ziming Li
    Qingquan Luo
    Cancer Immunology, Immunotherapy, 2021, 70 : 2313 - 2321
  • [32] Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients
    Kubo, Toshio
    Watanabe, Hiromi
    Ninomiya, Kiichiro
    Kudo, Kenichiro
    Minami, Daisuke
    Murakami, Etsuko
    Ochi, Nobuaki
    Ninomiya, Takashi
    Harada, Daijiro
    Yasugi, Masayuki
    Ichihara, Eiki
    Ohashi, Kadoaki
    Rai, Kammei
    Fujiwara, Keiichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (12) : 1447 - 1453
  • [33] Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
    Hao, Yuxuan
    Zhang, Xiaoye
    Yu, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer - A time for reassessment?
    Bunn, PA
    Mault, J
    Kelly, K
    CHEST, 2000, 117 (04) : 119S - 122S
  • [35] Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer
    Cao, Christopher
    Le, Anthony
    Bott, Matthew
    Yang, Chi-Fu Jeffrey
    Gossot, Dominique
    Melfi, Franca
    Tian, David H.
    Guo, Allen
    CURRENT ONCOLOGY, 2021, 28 (06) : 4686 - 4701
  • [36] Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study
    Dong, Weigang
    Yin, Yan
    Yang, Shengnan
    Liu, Bin
    Chen, Xi
    Wang, Lina
    Su, Yue
    Jiang, Yan
    Shi, Dongsheng
    Sun, Daqiang
    Qin, Jianwen
    BMC CANCER, 2024, 24 (01)
  • [37] Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study
    Weigang Dong
    Yan Yin
    Shengnan Yang
    Bin Liu
    Xi Chen
    Lina Wang
    Yue Su
    Yan Jiang
    Dongsheng Shi
    Daqiang Sun
    Jianwen Qin
    BMC Cancer, 24
  • [38] Real-World Outcomes of Patients with Resectable Early-Stage Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemoimmunotherapy
    Hazim, A.
    Xiao, A.
    Singh, A.
    Chung, K.
    dos Santos, P. A. Reck
    D'Cunha, J.
    Shanshal, M.
    Dimou, A.
    Parikh, K.
    Lou, Y.
    Manochakian, R.
    Leventakos, K.
    Molina, J.
    Mansfield, A.
    Ernani, V.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S546 - S547
  • [39] Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer (NSCLC)
    Liu, B.
    Wu, N.
    Yan, S.
    Zhang, E.
    Xu, L.
    Cheng, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S152 - S152
  • [40] Neoadjuvant chemotherapy for early stage non-small cell lung cancer
    Beitler, AL
    Urschel, JD
    Takita, H
    MEDICAL SCIENCE RESEARCH, 1998, 26 (12): : 853 - 854
12345